Insider Transaction Report for Ho Maykin

This filing details insider transactions by Ho Maykin, a director at AGIOS PHARMACEUTICALS, INC. On June 18, 2026, there were several transactions involving common stock and derivative securities. Ho Maykin acquired 2,816 shares of common stock, increasing their post-transaction holdings to 19,848 shares. Concurrently, there was a disposition of 2,816 restricted stock units (RSUs) and an acquisition of 2,927 RSUs, both with a transaction price of $0.0. Additionally, 14,950 stock options were acquired, also with a transaction price of $0.0, and an exercise price of $34.16. These RSUs and options are linked to AGIOS PHARMACEUTICALS, INC. common stock. The transactions were reported on Form 4, filed on June 23, 2026.